Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.16 USD
Change Today +0.04 / 0.56%
Volume 270.2K
CYTK On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

cytokinetics inc (CYTK) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/14 - $13.26
52 Week Low
10/13/14 - $3.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CYTOKINETICS INC (CYTK)

cytokinetics inc (CYTK) Related Businessweek News

No Related Businessweek News Found

cytokinetics inc (CYTK) Details

Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. It is involved in developing Tirasemtiv, a fast skeletal troponin activator that is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis; CK-2127107 that is in Phase I for the treatment of spinal muscle atrophy; and Omecamtiv mecarbil, which is in Phase II clinical trials for the potential treatment of heart failure. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure; and Astellas Pharma Inc. to advance novel therapies for diseases and medical conditions associated with muscle weakness. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.

92 Employees
Last Reported Date: 03/6/15
Founded in 1997

cytokinetics inc (CYTK) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $555.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $391.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $388.0K
Senior Vice President of Research & Developme...
Total Annual Compensation: $347.5K
Senior Vice President of Human Resources
Total Annual Compensation: $278.0K
Compensation as of Fiscal Year 2013.

cytokinetics inc (CYTK) Key Developments

Cytokinetics, Incorporated Announces Completion of Enrollment in COSMIC-HF

Cytokinetics, Incorporated announced the completion of Phase II Clinical Trial of Oral Omecamtiv Mecarbil in Patients with Heart Failure. COSMIC-HF is a double-blind, randomized, placebo-controlled, multicenter, study with two parts, a dose escalation phase and an expansion phase. The dose escalation phase assessed the pharmacokinetics and tolerability of three oral modified-release formulations of omecamtiv mecarbil in patients with heart failure and left ventricular systolic dysfunction and was used to select one formulation for further evaluation. The dose of omecamtiv mecarbil was 25 mg twice daily in the first escalation cohort and 50 mg twice daily in the second escalation cohort. The dose escalation phase of COSMIC-HF completed in 2013 and informed progression to the expansion phase. The ongoing expansion phase of the trial has enrolled approximately 450 patients randomized 1:1:1 to receive placebo, 25 mg, or 50 mg twice daily of omecamtiv mecarbil. Escalation to the 50 mg dose depends on the plasma concentration of omecamtiv mecarbil following 2 weeks of dosing with 25 mg twice daily. The primary objective of the expansion phase of COSMIC-HF is to characterize the safety, tolerability, and pharmacokinetics of oral omecamtiv mecarbil during 20 weeks of treatment. Secondary objectives are to assess changes from baseline in systolic ejection time, stroke volume, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, heart rate and N-terminal pro-brain natriuretic peptide (a biomarker associated with the severity of heart failure) during 20 weeks of treatment.

Cytokinetics, Incorporated Presents at 27th Annual ROTH Conference, Mar-09-2015 08:30 AM

Cytokinetics, Incorporated Presents at 27th Annual ROTH Conference, Mar-09-2015 08:30 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Robert I. Blum, Chief Executive Officer, President, Director and Chief Executive of the Biopharmaceutical Concern.

Cytokinetics, Incorporated Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Revenue Guidance for the Year 2015; Expects to Initiate Phase III Clinical Development Program in the Second Quarter of 2015 and Phase II Trial of Ck-2127107 in Patients with SMA in the Second Half of 2015

Cytokinetics, Incorporated reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenues of USD 21,758,000 against USD 24,349,000 a year ago. Operating income was USD 8,421,000 against USD 6,432,000 a year ago. Net income was USD 8,443,000 against USD 6,531,000 a year ago. Diluted net income per share was USD 0.23 against USD 0.21 a year ago. For the year, the company reported total revenues of USD 46,940,000 against USD 30,648,000 a year ago. Operating loss was USD 14,754,000 against USD 33,894,000 a year ago. Net loss was USD 14,646,000 against USD 33,717,000 a year ago. Basic and diluted net loss per share was USD 0.41 against USD 1.24 a year ago. The company also announced its financial guidance for 2015. The company anticipates cash revenue will be in the range of USD 40 to USD 43 million. This guidance includes approximately USD 30 million in revenue which will be deferred and recognized over a two year period ending in 2016 under generally accepted accounting principles. This guidance excludes the USD 15 million milestone payment earned in 2014 from Astellas and an estimated USD 3.6 million in non-cash related operating expenses primarily related to stock compensation expense. The company expects to initiate a Phase III clinical development program for tirasemtiv in patients with ALS in the second quarter of 2015. The company expects to initiate a Phase II trial of CK-2127107 in patients with SMA in the second half of 2015. The company expects enrollment of patients in the expansion phase of COSMIC-HF to conclude in the first quarter of 2015 and results from COSMIC-HF to be available in the second half of 2015. The company also expects to continue joint development activities in collaboration with Amgen directed to the potential advancement of omecamtiv mecarbil to Phase III clinical development.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTK:US $7.16 USD +0.04

CYTK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $2.10 USD -0.08
CTI BioPharma Corp $1.81 USD +0.01
Curis Inc $2.54 USD -0.04
Evotec AG €3.71 EUR -0.034
Exelixis Inc $2.54 USD +0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.6x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTOKINETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at